Lead Radiopharma Oncoinvent is a clinical stage radiopharmaceutical company focused on alpha-emitting therapies for metastatic cancers, presenting a ripe opportunity to target oncology stakeholders seeking novel targeted treatments and collaboration on late-stage trials.

Radspherin Focus The lead product Radspherin offers a receptor-independent alpha radiation approach designed to treat residual micrometastases in body cavities, providing a potentially differentiating offering for partnerships with academic medical centers and hospital systems specializing in advanced abdominal cancers.

Oslo Facilities Headquartered in Oslo with cGMP-compliant radiopharmaceutical manufacturing capabilities and modern labs, enabling potential co-development, technology licensing, or contract manufacturing collaborations for clinical trials and scale-up.

Strategic Merger Recent merger with BerGenBio and leadership hires such as a new CFO signal a dynamic corporate trajectory, suggesting sales conversations around joint venture structures, equity partnerships, or strategic alliances to accelerate product development and market entry.

Funding & Momentum With a funding base of about 72 million and ongoing communications about key milestones, there are opportunities to position for strategic investment, collaboration grants, and milestone-driven deals with pharma or biotech entities seeking radiopharma assets.